



## AVITA Medical to Host Investor Webinar Briefing

**VALENCIA, Calif., February 13, 2026** (GLOBE NEWSWIRE) — AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2026, at 2:00 p.m. Pacific Standard Time (February 19, 2026, at 9:00 a.m. Australian Eastern Daylight Time).

The webinar presentation will cover financial and business results from AVITA Medical’s recent fourth-quarter and full-year 2025 earnings webcast and will conclude with a Q&A session. Participants are invited to submit their questions via the registration page.

To register for the presentation, please follow this Zoom link:

[https://us06web.zoom.us/webinar/register/WN\\_F\\_lDbJWLS1SQqUKIjfwFWQ](https://us06web.zoom.us/webinar/register/WN_F_lDbJWLS1SQqUKIjfwFWQ)

A replay will be available on the AVITA Medical website at: <https://ir.avitamedical.com/>

### **About AVITA Medical, Inc.**

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, RECELL is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds. RECELL and RECELL GO® have received the CE mark in Europe; and RECELL is TGA-registered in Australia, and has PMDA approval in Japan.

To learn more, visit [www.avitamedical.com](http://www.avitamedical.com).

### **Investor & Media Contact:**

Ben Atkins

Phone +1-805 341 1571

[investor@avitamedical.com](mailto:investor@avitamedical.com)

[media@avitamedical.com](mailto:media@avitamedical.com)

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.